Tissue penetration of antifungal agents

Clinical Microbiology Reviews

Volumn 27, Issue 1, 2014, Pages 68-88

  Felton, Timothy ^a,b   Troke, Peter F ^c   Hope, William W ^b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c The Old Court ^*  (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; KETOCONAZOLE; MICAFUNGIN; POSACONAZOLE; VORICONAZOLE; XENOBIOTIC AGENT;

BONE; BRAIN; BRONCHUS SECRETION; CEREBROSPINAL FLUID; CHEEK MUCOSA; DRUG PENETRATION; ESOPHAGUS; EYE; GENITAL SYSTEM; HEART; HUMAN; KIDNEY; LIVER; LUNG; LUNG LYMPH; MUSCLE; NAIL; NONHUMAN; PANCREAS; PERITONEUM; PHARMACODYNAMICS; PLEURA FLUID; REVIEW; SALIVA; SKIN; SPLEEN; SPUTUM;

ANIMALS; ANTIFUNGAL AGENTS; HUMANS; MYCOSES;

EID: 84891711945     PISSN: 08938512     EISSN: 10986618     Source Type: Journal    
DOI: 10.1128/CMR.00046-13     Document Type: Review

References (263)

1. Pfaller MA, Diekema DJ. 2010. Epidemiology of invasive mycoses in North America. Crit. Rev. Microbiol. 36:1-53. http://dx.doi.org/10.3109 /10408410903241444.
2. Pfaller MA, Pappas PG, Wingard JR. 2006. Invasive fungal pathogens: current epidemiological trends. Clin. Infect. Dis. 43:S3-S14. http://dx.doi.org/10.1086/504490.
3. Lortholary O, Gangneux JP, Sitbon K, Lebeau B, de Monbrison F, Le Strat Y, Coignard B, Dromer F, Bretagne S. 2011. Epidemiological trends in invasive aspergillosis in France: the SAIF network (2005-2007). Clin. Microbiol. Infect. 17:1882-1889. http://dx.doi.org/10.1111/j.1469-0691.2011.03548.x.
4. Nivoix Y, Velten M, Letscher-Bru V, Moghaddam A, Natarajan-Ame S, Fohrer C, Lioure B, Bilger K, Lutun P, Marcellin L, Launoy A, Freys G, Bergerat JP, Herbrecht R. 2008. Factors associated with overall and attributable mortality in invasive aspergillosis. Clin. Infect. Dis. 47: 1176-1184. http://dx.doi.org/10.1086/592255.
5. Andes DR, Safdar N, Baddley JW, Playford G, Reboli AC, Rex JH, Sobel JD, Pappas PG, Kullberg BJ. 2012. Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. Clin. Infect. Dis. 54:1110-1122. http://dx.doi.org/10.1093/cid/cis021.
6. Pfaller MA, Diekema DJ. 2007. Epidemiology of invasive candidiasis: a persistent public health problem. Clin. Microbiol. Rev. 20:133-163. http: //dx.doi.org/10.1128/CMR.00029-06.
7. Wenzel RP, Gennings C. 2005. Bloodstream infections due to Candida species in the intensive care unit: identifying especially high-risk patients to determine prevention strategies. Clin. Infect. Dis. 41:S389-S393. http://dx.doi.org/10.1086/430923.
8. Hope WW, Drusano GL. 2009. Antifungal pharmacokinetics and pharmacodynamics: bridging from the bench to bedside. Clin. Microbiol. Infect. 15:602-612. http://dx.doi.org/10.1111/j.1469-0691.2009.02913.x.
9. Guinea J, Torres-Narbona M, Gijon P, Munoz P, Pozo F, Pelaez T, de Miguel J, Bouza E. 2010. Pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: incidence, risk factors, and outcome. Clin. Microbiol. Infect. 16:870-877. http://dx.doi.org/10.1111/j.1469-0691.2009.03015.x.
10. Meersseman W, Vandecasteele SJ, Wilmer A, Verbeken E, Peetermans WE, Van Wijngaerden E. 2004. Invasive aspergillosis in critically ill patients without malignancy. Am. J. Respir. Crit. Care Med. 170:621-625. http://dx.doi.org/10.1164/rccm.200401-093OC.
11. Drusano GL. 2005. Infection site concentrations: their therapeutic importance and the macrolide and macrolide-like class of antibiotics. Pharmacotherapy 25:150S-158S. http://dx.doi.org/10.1592/phco.2005.25.12part2.150S.
12. Rodvold KA, Yoo L, George JM. 2011. Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antifungal, antitubercular and miscellaneous anti-infective agents. Clin. Pharmacokinet. 50: 689-704. http://dx.doi.org/10.2165/11592900-000000000-00000.
13. Muller M, de la Pena A, Derendorf H. 2004. Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: distribution in tissue. Antimicrob. Agents Chemother. 48:1441-1453. http://dx.doi.org/10.1128/AAC.48.5.1441-1453.2004.
14. Stein GE, Wells EM. 2010. The importance of tissue penetration in achieving successful antimicrobial treatment of nosocomial pneumonia and complicated skin and soft-tissue infections caused by methicillinresistant Staphylococcus aureus: vancomycin and linezolid. Curr. Med. Res. Opin. 26:571-588. http://dx.doi.org/10.1185/03007990903512057.
15. Theuretzbacher U. 2007. Tissue penetration of antibacterial agents: how should this be incorporated into pharmacodynamic analyses? Curr. Opin. Pharmacol. 7:498-504. http://dx.doi.org/10.1016/j.coph.2007.05.003.
16. O'Day DM, Head SW. 2006. Ocular pharmacology of antifungal drugs, p 24. In Tasman W, Jaeger EA (ed), Duane's ophthalmology, vol 2. Foundations. Lippincott Williams & Wilkins, Philadelphia, PA.
17. Bellmann R. 2007. Clinical pharmacokinetics of systemically administered antimycotics. Curr. Clin. Pharmacol. 2:37-58. http://dx.doi.org/10.2174/157488407779422311.
18. Kethireddy S, Andes D. 2007. CNS pharmacokinetics of antifungal agents. Expert Opin. Drug Metab. Toxicol. 3:573-581. http://dx.doi.org /10.1517/17425255.3.4.573.
19. Eltoukhy N, Crank C. 2010. Antifungal distribution into cerebrospinal fluid, vitreous humour, bone and other difficult sites. Curr. Fungal Infect. Rep. 4:111-119. http://dx.doi.org/10.1007/s12281-010-0016-8.
20. Andes D, Craig WA. 2002. Animal model pharmacokinetics and pharmacodynamics: a critical review. Int. J. Antimicrob. Agents 19:261-268. http://dx.doi.org/10.1016/S0924-8579(02)00022-5.
21. Zeitlinger MA, Derendorf H, Mouton JW, Cars O, Craig WA, Andes D, Theuretzbacher U. 2011. Protein binding: do we ever learn? Antimicrob. Agents Chemother. 55:3067-3074. http://dx.doi.org/10.1128/AAC.01433-10.
22. Lignell A, Lowdin E, Cars O, Chryssanthou E, Sjolin J. 2011. Posaconazole in human serum: a greater pharmacodynamic effect than predicted by the non-protein-bound serum concentration. Antimicrob. Agents Chemother. 55:3099-3104. http://dx.doi.org/10.1128/AAC.01671-10.
23. Kiem S, Schentag JJ. 2008. Interpretation of antibiotic concentration ratios measured in epithelial lining fluid. Antimicrob. Agents Chemother. 52:24-36. http://dx.doi.org/10.1128/AAC.00133-06.
24. Liu P, Muller M, Derendorf H. 2002. Rational dosing of antibiotics: the use of plasma concentrations versus tissue concentrations. Int. J. Antimicrob. Agents 19:285-290. http://dx.doi.org/10.1016/S0924-8579(02)00024-9.
25. Miyama T, Takanaga H, Matsuo H, Yamano K, Yamamoto K, Iga T, Naito M, Tsuruo T, Ishizuka H, Kawahara Y, Sawada Y. 1998. P-glycoprotein-mediated transport of itraconazole across the blood-brain barrier. Antimicrob. Agents Chemother. 42:1738-1744.
26. Sandhu P, Lee W, Xu X, Leake BF, Yamazaki M, Stone JA, Lin JH, Pearson PG, Kim RB. 2005. Hepatic uptake of the novel antifungal agent caspofungin. Drug Metab. Dispos. 33:676-682. http://dx.doi.org/10.1124/dmd.104.003244.
27. Bazzoli C, Jullien V, Le Tiec C, Rey E, Mentre F, Taburet AM. 2010. Intracellular pharmacokinetics of antiretroviral drugs in HIV-infected patients, and their correlation with drug action. Clin. Pharmacokinet. 49:17-45. http://dx.doi.org/10.2165/11318110-000000000-00000.
28. Lestner JM, Howard SJ, Goodwin J, Gregson L, Majithiya J, Walsh TJ, Jensen GM, Hope WW. 2010. Pharmacokinetics and pharmacodynamics of amphotericin B deoxycholate, liposomal amphotericin B, and amphotericin B lipid complex in an in vitro model of invasive pulmonary aspergillosis. Antimicrob. Agents Chemother. 54:3432-3441. http://dx.doi.org/10.1128/AAC.01586-09.
29. Clemons KV, Schwartz JA, Stevens DA. 2012. Experimental central nervous system aspergillosis therapy: efficacy, drug levels and localization, immunohistopathology, and toxicity. Antimicrob. Agents Chemother. 56:4439-4449. http://dx.doi.org/10.1128/AAC.06015-11.
30. Bekersky I, Boswell GW, Hiles R, Fielding RM, Buell D, Walsh TJ. 2000. Safety, toxicokinetics and tissue distribution of long-term intravenous liposomal amphotericin B (AmBisome): a 91-day study in rats. Pharm. Res. 17:1494-1502. http://dx.doi.org/10.1023/A:1007605024942.
31. Louie A, Deziel M, Liu W, Drusano MF, Gumbo T, Drusano GL. 2005. Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity. Antimicrob. Agents Chemother. 49:5058-5068. http://dx.doi.org/10.1128/AAC.49.12.5058-5068.2005.
32. Jahn B, Rampp A, Dick C, Jahn A, Palmer M, Bhakdi S. 1998. Accumulation of amphotericin B in human macrophages enhances activity against Aspergillus fumigatus conidia: quantification of conidial kill at the single-cell level. Antimicrob. Agents Chemother. 42:2569-2575.
33. Campoli P, Al Abdallah Q, Robitaille R, Solis NV, Fielhaber JA, Kristof AS, Laverdiere M, Filler SG, Sheppard DC. 2011. Concentration of antifungal agents within host cell membranes: a new paradigm governing the efficacy of prophylaxis. Antimicrob. Agents Chemother. 55:5732-5739. http://dx.doi.org/10.1128/AAC.00637-11.
34. Andes D. 2003. Pharmacokinetics and pharmacodynamics in the development of antifungal compounds. Curr. Opin. Invest. Drugs 4:991-998.
35. Chang T, Olson JA, Proffitt RT, Adler-Moore JP. 2010. Differences in tissue drug concentrations following intravenous versus intraperitoneal treatment with amphotericin B deoxycholate or liposomal amphotericin B. Med. Mycol. 48:430-435. http://dx.doi.org/10.3109/13693780903208249.
36. Torrado JJ, Espada R, Ballesteros MP, Torrado-Santiago S. 2008. Amphotericin B formulations and drug targeting. J. Pharm. Sci. 97: 2405-2425. http://dx.doi.org/10.1002/jps.21179.
37. Fielding RM, Singer AW, Wang LH, Babbar S, Guo LS. 1992. Relationship of pharmacokinetics and drug distribution in tissue to increased safety of amphotericin B colloidal dispersion in dogs. Antimicrob. Agents Chemother. 36:299-307. http://dx.doi.org/10.1128/AAC.36.2.299.
38. Smith PJ, Olson JA, Constable D, Schwartz J, Proffitt RT, Adler-Moore JP. 2007. Effects of dosing regimen on accumulation, retention and prophylactic efficacy of liposomal amphotericin B. J. Antimicrob. Chemother. 59:941-951. http://dx.doi.org/10.1093/jac/dkm077.
39. Andes D, Safdar N, Marchillo K, Conklin R. 2006. Pharmacokineticpharmacodynamic comparison of amphotericin B (AMB) and two lipidassociated AMB preparations, liposomal AMB and AMB lipid complex, in murine candidiasis models. Antimicrob. Agents Chemother. 50:674-684. http://dx.doi.org/10.1128/AAC.50.2.674-684.2006.
40. Pyrgos V, Mickiene D, Sein T, Cotton M, Fransesconi A, Mizrahi I, Donoghue M, Bundrant N, Kim SY, Hardwick M, Shoham S, Walsh TJ. 2010. Effects of immunomodulatory and organism-associated molecules on the permeability of an in vitro blood-brain barrier model to amphotericin B and fluconazole. Antimicrob. Agents Chemother. 54: 1305-1310. http://dx.doi.org/10.1128/AAC.01263-09.
41. Pea F. 2013. Plasma pharmacokinetics of antimicrobial agents in critically ill patients. Curr. Clin. Pharmacol. 8:5-12. http://dx.doi.org/10.2174/1574884711308010003.
42. Nguyen TH, Hoppe-Tichy T, Geiss HK, Rastall AC, Swoboda S, Schmidt J, Weigand MA. 2007. Factors influencing caspofungin plasma concentrations in patients of a surgical intensive care unit. J. Antimicrob. Chemother. 60:100-106. http://dx.doi.org/10.1093/jac/dkm125.
43. Kennedy AL, Wasan KM. 1999. Preferential distribution of amphotericin B lipid complex into human HDL3 is a consequence of high density lipoprotein coat lipid content. J. Pharm. Sci. 88:1149-1155. http://dx.doi.org/10.1021/js990101z.
44. Wasan KM, Kennedy AL, Cassidy SM, Ramaswamy M, Holtorf L, Chou JW, Pritchard PH. 1998. Pharmacokinetics, distribution in serum lipoproteins and tissues, and renal toxicities of amphotericin B and amphotericin B lipid complex in a hypercholesterolemic rabbit model: single-dose studies. Antimicrob. Agents Chemother. 42:3146-3152.
45. Wildfeuer A, Reisert I, Laufen H. 1992. Subcellular distribution and antifungal effects of fluconazole in human phagocytic cells. Demonstration of the antifungal agent in neutrophil polymorphonuclear leucocytes and monocytes by autoradiography and electron micrography. Arzneimittelforschung 42:1049-1052.
46. Perfect JR, Savani DV, Durack DT. 1993. Uptake of itraconazole by alveolar macrophages. Antimicrob. Agents Chemother. 37:903-904. http://dx.doi.org/10.1128/AAC.37.4.903.
47. Willems L, van der Geest R, de Beule K. 2001. Itraconazole oral solution and intravenous formulations: a review of pharmacokinetics and pharmacodynamics. J. Clin. Pharm. Ther. 26:159-169. http://dx.doi.org/10.1046/j.1365-2710.2001.00338.x.
48. Hope WW. 2012. Population pharmacokinetics of voriconazole in adults. Antimicrob. Agents Chemother. 56:526-531. http://dx.doi.org /10.1128/AAC.00702-11.
49. Dromer F, Mathoulin S, Dupont B, Brugiere O, Letenneur L. 1996. Comparison of the efficacy of amphotericin B and fluconazole in the treatment of cryptococcosis in human immunodeficiency virus-negative patients: retrospective analysis of 83 cases. French Cryptococcosis Study Group. Clin. Infect. Dis. 22(Suppl 2):S154-S160.
50. Denning DW, Tucker RM, Hanson LH, Hamilton JR, Stevens DA. 1989. Itraconazole therapy for cryptococcal meningitis and cryptococcosis. Arch. Intern. Med. 149:2301-2308. http://dx.doi.org/10.1001/archinte.1989.00390100107024.
51. Mouton JW, Theuretzbacher U, Craig WA, Tulkens PM, Derendorf H, Cars O. 2008. Tissue concentrations: do we ever learn? J. Antimicrob. Chemother. 61:235-237. http://dx.doi.org/10.1093/jac/dkm476.
52. Collette N, van der Auwera P, Lopez AP, Heymans C, Meunier F. 1989. Tissue concentrations and bioactivity of amphotericin B in cancer patients treated with amphotericin B-deoxycholate. Antimicrob. Agents Chemother. 33:362-368. http://dx.doi.org/10.1128/AAC.33.3.362.
53. Collette N, Van der Auwera P, Meunier F, Lambert C, Sculier JP, Coune A. 1991. Tissue distribution and bioactivity of amphotericin B administered in liposomes to cancer patients. J. Antimicrob. Chemother. 27:535-548. http://dx.doi.org/10.1093/jac/27.4.535.
54. Christiansen KJ, Bernard EM, Gold JW, Armstrong D. 1985. Distribution and activity of amphotericin B in humans. J. Infect. Dis. 152: 1037-1043. http://dx.doi.org/10.1093/infdis/152.5.1037.
55. Joukhadar C, Thallinger C, Poppl W, Kovar F, Konz KH, Joukhadar SM, Traunmuller F. 2009. Concentrations of voriconazole in healthy and inflamed lung in rats. Antimicrob. Agents Chemother. 53:2684-2686. http://dx.doi.org/10.1128/AAC.00885-08.
56. Conte JE, Jr, Golden JA, Kipps J, McIver M, Zurlinden E. 2004. Intrapulmonary pharmacokinetics and pharmacodynamics of itraconazole and 14-hydroxyitraconazole at steady state. Antimicrob. Agents Chemother. 48:3823-3827. http://dx.doi.org/10.1128/AAC.48.10.3823-3827.2004.
57. Conte JE, Jr, Golden JA, Krishna G, McIver M, Little E, Zurlinden E. 2009. Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects. Antimicrob. Agents Chemother. 53:703-707. http://dx.doi.org/10.1128/AAC.00663-08.
58. Crandon JL, Banevicius MA, Fang AF, Crownover PH, Knauft RF, Pope JS, Russomanno JH, Shore E, Nicolau DP, Kuti JL. 2009. Bronchopulmonary disposition of intravenous voriconazole and anidulafungin given in combination to healthy adults. Antimicrob. Agents Chemother. 53:5102-5107. http://dx.doi.org/10.1128/AAC.01042-09.
59. Krishna G, Ma L, Beresford E, Tavakkol A, Martinho M, Yu X, Komjathy S. 2010. Skin concentrations and pharmacokinetics of posaconazole after oral administration. Antimicrob. Agents Chemother. 54:1807-1810. http://dx.doi.org/10.1128/AAC.01616-09.
60. Moriyama B, Torabi-Parizi P, Pratt AK, Henning SA, Pennick G, Shea YR, Roy Chowdhuri S, Rinaldi MG, Barrett AJ, Walsh TJ. 2010. Pharmacokinetics of liposomal amphotericin B in pleural fluid. Antimicrob. Agents Chemother. 54:1633-1635. http://dx.doi.org/10.1128/AAC.01438-09.
61. Nicasio AM, Tessier PR, Nicolau DP, Knauft RF, Russomanno J, Shore E, Kuti JL. 2009. Bronchopulmonary disposition of micafungin in healthy adult volunteers. Antimicrob. Agents Chemother. 53:1218-1220. http://dx.doi.org/10.1128/AAC.01386-08.
62. Walsh TJ, Goutelle S, Jelliffe RW, Golden JA, Little EA, DeVoe C, Mickiene D, Hayes M, Conte JE, Jr. 2010. Intrapulmonary pharmacokinetics and pharmacodynamics of micafungin in adult lung transplant patients. Antimicrob. Agents Chemother. 54:3451-3459. http://dx.doi.org/10.1128/AAC.01647-09.
63. Warn PA, Sharp A, Parmar A, Majithiya J, Denning DW, Hope WW. 2009. Pharmacokinetics and pharmacodynamics of a novel triazole, isavuconazole: mathematical modeling, importance of tissue concentrations, and impact of immune status on antifungal effect. Antimicrob. Agents Chemother. 53:3453-3461. http://dx.doi.org/10.1128/AAC.01601-08.
64. Soon RL, Ly NS, Rao G, Wollenberg L, Yang K, Tsuji B, Forrest A. 2013. Pharmacodynamic variability beyond that explained by MICs. Antimicrob. Agents Chemother. 57:1730-1735. http://dx.doi.org/10.1128 /AAC.01224-12.
65. Regazzi M, Billaud EM, Lefeuvre S, Stronati M. 2012. Pharmacokinetics of antifungal agents in neonates and young infants. Curr. Med. Chem. 19:4621-4632. http://dx.doi.org/10.2174/092986712803306402.
66. Djukic M, Munz M, Sörgel F, Holzgrabe U, Eiffert H, Nau R. 2012. Overton's rule helps to estimate the penetration of anti-infectives into patients' cerebrospinal fluid. Antimicrob. Agents Chemother. 56:979-988. http://dx.doi.org/10.1128/AAC.00437-11.
67. Brammer KW, Farrow PR, Faulkner JK. 1990. Pharmacokinetics and tissue penetration of fluconazole in humans. Rev. Infect. Dis. 12(Suppl 3): S318-S326. http://dx.doi.org/10.1093/clinids/12.Supplement_3.S318.
68. Tucker RM, Williams PL, Arathoon EG, Levine BE, Hartstein AI, Hanson LH, Stevens DA. 1988. Pharmacokinetics of fluconazole in cerebrospinal fluid and serum in human coccidioidal meningitis. Antimicrob. Agents Chemother. 32:369-373. http://dx.doi.org/10.1128 /AAC.32.3.369.
69. Foulds G, Brennan DR, Wajszczuk C, Catanzaro A, Garg DC, Knopf W, Rinaldi M, Weidler DJ. 1988. Fluconazole penetration into cerebrospinal fluid in humans. J. Clin. Pharmacol. 28:363-366. http://dx.doi.org /10.1002/j.1552-4604.1988.tb03159.x.
70. Manosuthi W, Chetchotisakd P, Nolen TL, Wallace D, Sungkanuparph S, Anekthananon T, Supparatpinyo K, Pappas PG, Larsen RA, Filler SG, Andes D. 2010. Monitoring and impact of fluconazole serum and cerebrospinal fluid concentration in HIV-associated cryptococcal meningitis-infected patients. HIV Med. 11:276-281. http://dx.doi.org /10.1111/j.1468-1293.2009.00778.x.
71. Fischman AJ, Alpert NM, Livni E, Ray S, Sinclair I, Callahan RJ, Correia JA, Webb D, Strauss HW, Rubin RH. 1993. Pharmacokinetics of 18F-labeled fluconazole in healthy human subjects by positron emission tomography. Antimicrob. Agents Chemother. 37:1270-1277. http: //dx.doi.org/10.1128/AAC.37.6.1270.
72. Thaler F, Bernard B, Tod M, Jedynak CP, Petitjean O, Derome P, Loirat P. 1995. Fluconazole penetration in cerebral parenchyma in humans at steady state. Antimicrob. Agents Chemother. 39:1154-1156. http://dx.doi.org/10.1128/AAC.39.5.1154.
73. Heykants J, Micheils M, Mueldermans W, Monbaliu J, Lavrijsen K, Van Peer A, Levron J, Woestenborghs R, Cauwenbergh G. 1987. The pharmacokinetics of itraconazole in animals and man: an overview, p 223-259. In Fromtling RA (ed), Recent trends in the discovery, development and evaluation of antifungal agents. J R Prous, Barcelona, Spain.
74. Verweij PE, Brinkman K, Kremer HP, Kullberg BJ, Meis JF. 1999. Aspergillus meningitis: diagnosis by non-culture-based microbiological methods and management. J. Clin. Microbiol. 37:1186-1189.
75. Imbert F, Jardin M, Fernandez C, Gantier JC, Dromer F, Baron G, Mentre F, Van Beijsterveldt L, Singlas E, Gimenez F. 2003. Effect of efflux inhibition on brain uptake of itraconazole in mice infected with Cryptococcus neoformans. Drug Metab. Dispos. 31:319-325. http://dx.doi.org/10.1124/dmd.31.3.319.
76. Lee JH, Shin JH, Lee MG. 2004. Pharmacokinetics, blood partition, and tissue distribution of itraconazole. Res. Commun. Mol. Pathol. Pharmacol. 115-116:203-215.
77. Perfect JR, Savani DV, Durack DT. 1986. Comparison of itraconazole and fluconazole in treatment of cryptococcal meningitis and Candida pyelonephritis in rabbits. Antimicrob. Agents Chemother. 29:579-583. http://dx.doi.org/10.1128/AAC.29.4.579.
78. Cauwenbergh G. 1993. Cryptococcal meningitis: the place of itraconazole. Mycoses 36:221-228.
79. Elter T, Sieniawski M, Gossmann A, Wickenhauser C, Schroder U, Seifert H, Kuchta J, Burhenne J, Riedel KD, Fatkenheuer G, Cornely OA. 2006. Voriconazole brain tissue levels in rhinocerebral aspergillosis in a successfully treated young woman. Int. J. Antimicrob. Agents 28: 262-265. http://dx.doi.org/10.1016/j.ijantimicag.2006.04.006.
80. Weiler S, Fiegl D, MacFarland R, Stienecke E, Bellmann-Weiler R, Dunzendorfer S, Joannidis M, Bellmann R. 2011. Human tissue distribution of voriconazole. Antimicrob. Agents Chemother. 55:925-928. http://dx.doi.org/10.1128/AAC.00949-10.
81. Denes E, Pichon N, Debette-Gratien M, Bouteille B, Gaulier JM. 2004. Pharmacokinetics of voriconazole in the cerebrospinal fluid of an immunocompromised patient with a brain abscess due to Aspergillus fumigatus. Clin. Infect. Dis. 39:603-604. http://dx.doi.org/10.1086/422526.
82. Schwartz S, Milatovic D, Thiel E. 1997. Successful treatment of cerebral aspergillosis with a novel triazole (voriconazole) in a patient with acute leukaemia. Br. J. Haematol. 97:663-665.
83. Lutsar I, Roffey S, Troke P. 2003. Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients. Clin. Infect. Dis. 37:728-732. http://dx.doi.org/10.1086 /377131.
84. Roffey SJ, Cole S, Comby P, Gibson D, Jezequel SG, Nedderman AN, Smith DA, Walker DK, Wood N. 2003. The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human. Drug Metab. Dispos. 31:731-741. http://dx.doi.org/10.1124/dmd.31.6.731.
85. Calcagno A, Baietto L, De Rosa FG, Tettoni MC, Libanore V, Bertucci R, D'Avolio A, Di Perri G. 2011. Posaconazole cerebrospinal concentrations in an HIV-infected patient with brain mucormycosis. J. Antimicrob. Chemother. 66:224-225. http://dx.doi.org/10.1093/jac/dkq385.
86. Reinwald M, Uharek L, Lampe D, Grobosch T, Thiel E, Schwartz S. 2009. Limited penetration of posaconazole into cerebrospinal fluid in an allogeneic stem cell recipient with invasive pulmonary aspergillosis. Bone Marrow Transpl. 44:269-270. http://dx.doi.org/10.1038/bmt.2009.17.
87. Ruping MJ, Albermann N, Ebinger F, Burckhardt I, Beisel C, Muller C, Vehreschild JJ, Kochanek M, Fatkenheuer G, Bangard C, Ullmann AJ, Herr W, Kolbe K, Hallek M, Cornely OA. 2008. Posaconazole concentrations in the central nervous system. J. Antimicrob. Chemother. 62:1468-1470. http://dx.doi.org/10.1093/jac/dkn409.
88. Calvo E, Pastor FJ, Rodriguez MM, Pujol I, Guarro J. 2010. Antifungal therapy in a murine model of disseminated infection by Cryptococcus gattii. Antimicrob. Agents Chemother. 54:4074-4077. http://dx.doi.org /10.1128/AAC.00172-10.
89. Calvo E, Pastor FJ, Rodriguez MM, Mayayo E, Salas V, Guarro J. 2010. Murine model of a disseminated infection by the novel fungus Fonsecaea monophora and successful treatment with posaconazole. Antimicrob. Agents Chemother. 54:919-923. http://dx.doi.org/10.1128/AAC.01284-09.
90. Vogelsinger H, Weiler S, Djanani A, Kountchev J, Bellmann-Weiler R, Wiedermann CJ, Bellmann R. 2006. Amphotericin B tissue distribution in autopsy material after treatment with liposomal amphotericin B and amphotericin B colloidal dispersion. J. Antimicrob. Chemother. 57: 1153-1160. http://dx.doi.org/10.1093/jac/dkl141.
91. Polak A. 1979. Pharmacokinetics of amphotericin B and flucytosine. Postgrad. Med. J. 55:667-670. http://dx.doi.org/10.1136/pgmj.55.647.667.
92. Groll AH, Giri N, Petraitis V, Petraitiene R, Candelario M, Bacher JS, Piscitelli SC, Walsh TJ. 2000. Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system. J. Infect. Dis. 182:274-282. http: //dx.doi.org/10.1086/315643.
93. Young RF, Gade G, Grinnell V. 1985. Surgical treatment for fungal infections in the central nervous system. J. Neurosurg. 63:371-381. http: //dx.doi.org/10.3171/jns.1985.63.3.0371.
94. LePage E. 1993. Using a ventricular reservoir to instill amphotericin B. J. Neurosci. Nurs. 25:212-217. http://dx.doi.org/10.1097/01376517-199308000-00004.
95. Shen H, Huo Z, Liu L, Lin Z. 2011. Stereotatic implantation of Ommaya reservoir in the management of brain abscesses. Br. J. Neurosurg. 25:636-640. http://dx.doi.org/10.3109/02688697.2010.534201.
96. Block ER, Bennett JE. 1972. Pharmacological studies with 5-fluorocytosine. Antimicrob. Agents Chemother. 1:476-482. http://dx.doi.org/10.1128/AAC.1.6.476.
97. Perfect JR, Dismukes WE, Dromer F, Goldman DL, Graybill JR, Hamill RJ, Harrison TS, Larsen RA, Lortholary O, Nguyen MH, Pappas PG, Powderly WG, Singh N, Sobel JD, Sorrell TC. 2010. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 50:291-322. http://dx.doi.org/10.1086/649858.
98. Begley DJ, Squires LK, Zlokovic BV, Mitrovic DM, Hughes CC, Revest PA, Greenwood J. 1990. Permeability of the blood-brain barrier to the immunosuppressive cyclic peptide cyclosporin A. J. Neurochem. 55: 1222-1230. http://dx.doi.org/10.1111/j.1471-4159.1990.tb03128.x.
99. Su Y, Sinko PJ. 2006. Drug delivery across the blood-brain barrier: why is it difficult? How to measure and improve it? Expert Opin. Drug Deliv. 3:419-435. http://dx.doi.org/10.1517/17425247.3.3.419.
100. Groll AH, Mickiene D, Petraitiene R, Petraitis V, Lyman CA, Bacher JS, Piscitelli SC, Walsh TJ. 2001. Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling. Antimicrob. Agents Chemother. 45:2845-2855. http: //dx.doi.org/10.1128/AAC.45.10.2845-2855.2001.
101. Warn PA, Livermore J, Howard S, Felton TW, Sharp A, Gregson L, Goodwin J, Petraitiene R, Petraitis V, Cohen-Wolkowiez M, Walsh TJ, Benjamin DK, Jr, Hope WW. 2012. Anidulafungin for neonatal hematogenous Candida meningoencephalitis: identification of candidate regimens for humans using a translational pharmacological approach. Antimicrob. Agents Chemother. 56:708-714. http://dx.doi.org/10.1128 /AAC.05826-11.
102. Damle B, Stogniew M, Dowell J. 2008. Pharmacokinetics and tissue distribution of anidulafungin in rats. Antimicrob. Agents Chemother. 52:2673-2676. http://dx.doi.org/10.1128/AAC.01596-07.
103. Hajdu R, Thompson R, Sundelof JG, Pelak BA, Bouffard FA, Dropinski JF, Kropp H. 1997. Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743,872). Antimicrob. Agents Chemother. 41:2339-2344.
104. Stone JA, Xu X, Winchell GA, Deutsch PJ, Pearson PG, Migoya EM, Mistry GC, Xi L, Miller A, Sandhu P, Singh R, deLuna F, Dilzer SC, Lasseter KC. 2004. Disposition of caspofungin: role of distribution in determining pharmacokinetics in plasma. Antimicrob. Agents Chemother. 48: 815-823. http://dx.doi.org/10.1128/AAC.48.3.815-823.2004.
105. Hsue G, Napier JT, Prince RA, Chi J, Hospenthal DR. 2004. Treatment of meningeal coccidioidomycosis with caspofungin. J. Antimicrob. Chemother. 54:292-294. http://dx.doi.org/10.1093/jac/dkh306.
106. Lat A, Thompson GR, 3rd, Rinaldi MG, Dorsey SA, Pennick G, Lewis JS, 2nd. 2010. Micafungin concentrations from brain tissue and pancreatic pseudocyst fluid. Antimicrob. Agents Chemother. 54:943-944. http: //dx.doi.org/10.1128/AAC.01294-09.
107. Yamada N, Kumada K, Kishino S, Mochizuki N, Ohno K, Ogura S. 2011. Distribution of micafungin in the tissue fluids of patients with invasive fungal infections. J. Infect. Chemother. 17:731-734. http://dx.doi.org/10.1007/s10156-011-0240-3.
108. Hope WW, Mickiene D, Petraitis V, Petraitiene R, Kelaher AM, Hughes JE, Cotton MP, Bacher J, Keirns JJ, Buell D, Heresi G, Benjamin DK, Jr, Groll AH, Drusano GL, Walsh TJ. 2008. The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous Candida meningoencephalitis: implications for echinocandin therapy in neonates. J. Infect. Dis. 197:163-171. http://dx.doi.org/10.1086/524063.
109. Riddell J, IV, Comer GM, Kauffman CA. 2011. Treatment of endogenous fungal endophthalmitis: focus on new antifungal agents. Clin. Infect. Dis. 52:648-653. http://dx.doi.org/10.1093/cid/ciq204.
110. Tod M, Lortholary O, Padoin C, Chaine G. 1997. Intravenous penetration of fluconazole during endophthalmitis. Clin. Microbiol. Infect. 3:143-144. http://dx.doi.org/10.1111/j.1469-0691.1997.tb00269.x.
111. Urbak SF, Degn T. 1994. Fluconazole in the management of fungal ocular infections. Ophthalmologica 208:147-156. http://dx.doi.org/10.1159/000310473.
112. Aust R, Kruse FE, Wildfeuer A, Pfaff G, Rohrschneider K, Volcker HE. 1995. Fluconazole level in aqueous humor after oral drug administration in humans. Ophthalmologe 92:829-832.
113. Spriet I, Delaere L, Lagrou K, Peetermans WE, Maertens J, Willems L. 2009. Intraocular penetration of voriconazole and caspofungin in a patient with fungal endophthalmitis. J. Antimicrob. Chemother. 64:877-878. http://dx.doi.org/10.1093/jac/dkp306.
114. Hariprasad SM, Mieler WF, Holz ER, Gao H, Kim JE, Chi J, Prince RA. 2004. Determination of vitreous, aqueous, and plasma concentration of orally administered voriconazole in humans. Arch. Ophthalmol. 122:42-47. http://dx.doi.org/10.1001/archopht.122.1.42.
115. O'Day DM, Head WS, Robinson RD, Stern WH, Freeman JM. 1985. Intraocular penetration of systemically administered antifungal agents. Curr. Eye Res. 4:131-134. http://dx.doi.org/10.3109/02713688508999978.
116. Walsh A, Haft DA, Miller MH, Loran MR, Friedman AH. 1978. Ocular penetration of 5-fluorocytosine. Invest. Ophthalmol. Vis. Sci. 17:691-694.
117. Hariprasad SM, Mieler WF, Lin TK, Sponsel WE, Graybill JR. 2008. Voriconazole in the treatment of fungal eye infections: a review of current literature. Br. J. Ophthalmol. 92:871-878. http://dx.doi.org/10.1136 /bjo.2007.136515.
118. Kinoshita J, Iwata N, Ohba M, Kimotsuki T, Yasuda M. 2011. Mechanism of voriconazole-induced transient visual disturbance: reversible dysfunction of retinal ON-bipolar cells in monkeys. Invest. Ophthalmol. Vis. Sci. 52:5058-5063. http://dx.doi.org/10.1167/iovs.11-7183.
119. Laties AM, Fraunfelder FT, Tomaszewski K, Goodrich J, Moreira AT, Sato MT, de Queiroz-Telles F. 2010. Long-term visual safety of voriconazole in adult patients with paracoccidioidomycosis. Clin. Ther. 32: 2207-2217. http://dx.doi.org/10.1016/S0149-2918(10)80024-4.
120. Savani DV, Perfect JR, Cobo LM, Durack DT. 1987. Penetration of new azole compounds into the eye and efficacy in experimental Candida endophthalmitis. Antimicrob. Agents Chemother. 31:6-10. http://dx.doi.org/10.1128/AAC.31.1.6.
121. Mochizuki K, Niwa Y, Ishida K, Kawakami H. 2013. Intraocular penetration of itraconazole in patient with fungal endophthalmitis. Int. Ophthalmol. 33:579-581. http://dx.doi.org/10.1007/s10792-012-9696-0.
122. Heykants J, Van Peer A, Van de Velde V, Van Rooy P, Meuldermans W, Lavrijsen K, Woestenborghs R, Van Cutsem J, Cauwenbergh G. 1989. The clinical pharmacokinetics of itraconazole: an overview. Mycoses 32:67-87.
123. Fisher JF, Taylor AT, Clark J, Rao R, Espinel-Ingroff A. 1983. Penetration of amphotericin B into the human eye. J. Infect. Dis. 147:164. http://dx.doi.org/10.1093/infdis/147.1.164.
124. Green WR, Bennett JE, Goos RD. 1965. Ocular penetration of amphotericin B: a report of laboratory studies and a case peport of postsurgical Cephalosporium endophthalmitis. Arch. Ophthalmol. 73:769-775. http://dx.doi.org/10.1001/archopht.1965.00970030771004.
125. Goldblum D, Rohrer K, Frueh BE, Theurillat R, Thormann W, Zimmerli S. 2002. Ocular distribution of intravenously administered lipid formulations of amphotericin B in a rabbit model. Antimicrob. Agents Chemother. 46:3719-3723. http://dx.doi.org/10.1128/AAC.46.12.3719-3723.2002.
126. Goldblum D, Fausch K, Frueh BE, Theurillat R, Thormann W, Zimmerli S. 2007. Ocular penetration of caspofungin in a rabbit uveitis model. Graefes Arch. Clin. Exp. Ophthalmol. 245:825-833. http://dx.doi.org/10.1007/s00417-006-0460-x.
127. Groll AH, Mickiene D, Petraitis V, Petraitiene R, Ibrahim KH, Piscitelli SC, Bekersky I, Walsh TJ. 2001. Compartmental pharmacokinetics and tissue distribution of the antifungal echinocandin lipopeptide micafungin (FK463) in rabbits. Antimicrob. Agents Chemother. 45:3322-3327. http://dx.doi.org/10.1128/AAC.45.12.3322-3327.2001.
128. Livermore JL, Felton TW, Abbott J, Sharp A, Goodwin J, Gregson L, Warn PA, Howard SJ, Hope WW. 2013. Pharmacokinetics and pharmacodynamics of anidulafungin for experimental Candida endophthalmitis: insights into the utility of echinocandins for treatment of a potentially sight-threatening infection. Antimicrob. Agents Chemother. 57: 281-288. http://dx.doi.org/10.1128/AAC.01387-12.
129. Suzuki T, Uno T, Chen G, Ohashi Y. 2008. Ocular distribution of intravenously administered micafungin in rabbits. J. Infect. Chemother. 14:204-207. http://dx.doi.org/10.1007/s10156-008-0612-5.
130. Gauthier GM, Nork TM, Prince R, Andes D. 2005. Subtherapeutic ocular penetration of caspofungin and associated treatment failure in Candida albicans endophthalmitis. Clin. Infect. Dis. 41:e27-e28. http: //dx.doi.org/10.1086/431761.
131. Mochizuki K, Suemori S, Udo K, Komori S, Ohkusu K, Yamada N, Ogura S. 2011. Intraocular penetration of micafungin in patient with Candida albicans endophthalmitis. J. Ocul. Pharmacol. Ther. 27:531-533. http://dx.doi.org/10.1089/jop.2011.0026.
132. Mochizuki K, Murase H, Yasuda Y, Suematsu H, Yamagishi Y, Mikamo H. 2012. Discrepancy of in-vitro data and clinical efficacy of micafungin against Candida tropicalis endophthalmitis. J. Infect. Chemother. 18:786-789. http://dx.doi.org/10.1007/s10156-012-0370-2.
133. Ho KM, Duff O, Chambers D, Murray R. 2008. Meta-analysis of nebulized amphotericin B to prevent or treat pulmonary aspergillosis in immunosuppressed animals. Trans. Infect. Dis. 10:168-176. http://dx.doi.org/10.1111/j.1399-3062.2007.00290.x.
134. Kuiper L, Ruijgrok EJ. 2009. A review on the clinical use of inhaled amphotericin B. J. Aerosol. Med. Pulm. Drug Deliv. 22:213-227. http: //dx.doi.org/10.1089/jamp.2008.0715.
135. Monforte V, Ussetti P, Gavalda J, Bravo C, Laporta R, Len O, Garcia-Gallo CL, Tenorio L, Sole J, Roman A. 2010. Feasibility, tolerability, and outcomes of nebulized liposomal amphotericin B for Aspergillus infection prevention in lung transplantation. J. Heart Lung Transplant. 29:523-530. http://dx.doi.org/10.1016/j.healun.2009.11.603.
136. Wildfeuer A, Laufen H, Schmalreck AF, Yeates RA, Zimmermann T. 1997. Fluconazole: comparison of pharmacokinetics, therapy and in vitro susceptibility. Mycoses 40:259-265. http://dx.doi.org/10.1111/j.1439-0507.1997.tb00230.x.
137. Vaden SL, Heit MC, Hawkins EC, Manaugh C, Riviere JE. 1997. Fluconazole in cats: pharmacokinetics following intravenous and oral administration and penetration into cerebrospinal fluid, aqueous humour and pulmonary epithelial lining fluid. J. Vet. Pharmacol. Ther. 20:181-186. http://dx.doi.org/10.1111/j.1365-2885.1997.tb00093.x.
138. Mauric O, Thallinger C, Kugler SA, Joukhadar SM, Kovar FM, Konz KH, Graninger W, Joukhadar C. 2011. The ability of fluconazole to penetrate into ventilated, healthy and inflamed lung tissue in a model of severe sepsis in rats. Pharmacology 87:130-134. http://dx.doi.org/10.1159/000323738.
139. Coronel B, Levron JC, Dorez D, Van Devenne A, Archimbaud E, Mercatello A. 2000. Itraconazole lung concentrations in haematological patients. Mycoses 43:125-127. http://dx.doi.org/10.1046/j.1439-0507.2000.00565.x.
140. Watkins DN, Badcock NR, Thompson PJ. 1992. Itraconazole concentrations in airway fluid and tissue. Br. J. Clin. Pharmacol. 33:206-207. http://dx.doi.org/10.1111/j.1365-2125.1992.tb04030.x.
141. Weiler S, Bellmann-Weiler R, Dunzendorfer S, Joannidis M, Bellmann R. 2008. Voriconazole and target-site penetration into human tissue. BMC Pharmacol. 8:A57. http://dx.doi.org/10.1186/1471-2210-8-S1-A57.
142. Capitano BP, Husain B, Zhang S, Paterson S, Studer D, McCurry S K., Venkataramanan R. 2006. Intrapulmonary penetration of voriconazole in patients receiving an oral prophylactic regimen. Antimicrob. Agents Chemother. 50:1878-1880. http://dx.doi.org/10.1128/AAC.50.5.1878-1880.2006.
143. Conte JE, DeVoe C, Little E, Golden JA. 2010. Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients. Antimicrob. Agents Chemother. 54:3609-3613. http://dx.doi.org/10.1128/AAC.01396-09.
144. Bellmann R, Egger P, Wiedermann CJ. 2003. Differences in pharmacokinetics of amphotericin B lipid formulations despite clinical equivalence. Clin. Infect. Dis. 36:1500-1501. http://dx.doi.org/10.1086/374876.
145. Groll AH, Walsh TJ. 2006. Antifungal efficacy and pharmacodynamics of posaconazole in experimental models of invasive fungal infections. Mycoses 49(Suppl 1):7-16. http://dx.doi.org/10.1111/j.1439-0507.2006.01296.x.
146. Groll AH, Lyman CA, Petraitis V, Petraitiene R, Armstrong D, Mickiene D, Alfaro RM, Schaufele RL, Sein T, Bacher J, Walsh TJ. 2006. Compartmentalized intrapulmonary pharmacokinetics of amphotericin B and its lipid formulations. Antimicrob. Agents Chemother. 50:3418-3423. http://dx.doi.org/10.1128/AAC.00241-06.
147. Weiler S, Falkensammer G, Hammerer-Lercher A, Anliker M, Vogelsinger H, Joannidis M, Dunzendorfer S, Stein M, Bellmann R. 2009. Pulmonary epithelial lining fluid concentrations after use of systemic amphotericin B lipid formulations. Antimicrob. Agents Chemother. 53: 4934-4937. http://dx.doi.org/10.1128/AAC.00796-09.
148. Watanabe A, Matsumoto K, Igari H, Uesato M, Yoshida S, Nakamura Y, Morita K, Shibuya K, Matsubara H, Yoshino I, Kamei K. 2010. Comparison between concentrations of amphotericin B in infected lung lesion and in uninfected lung tissue in a patient treated with liposomal amphotericin B (AmBisome). Int. J. Infect. Dis. 14(Suppl 3):e220-e223. http://dx.doi.org/10.1016/j.ijid.2009.07.020.
149. Burkhardt O, Ellis S, Burhenne H, Kaever V, Hadem J, Kielstein JT, Welte T. 2009. High caspofungin levels in alveolar cells of a lung transplant patient with suspected pulmonary aspergillosis. Int. J. Antimicrob. Agents 34:491-492. http://dx.doi.org/10.1016/j.ijantimicag.2009.04.002.
150. Niwa T, Yokota Y, Tokunaga A, Yamato Y, Kagayama A, Fujiwara T, Hatakeyama J, Anezaki M, Ohtsuka Y, Takagi A. 2004. Tissue distribution after intravenous dosing of micafungin, an antifungal drug, to rats. Biol. Pharm. Bull. 27:1154-1156. http://dx.doi.org/10.1248/bpb.27.1154.
151. Hoeprich PD, Merry JM, Gunther R, Franti CE. 1987. Entry of five antifungal agents into the ovine lung. Antimicrob. Agents Chemother. 31:1234-1237. http://dx.doi.org/10.1128/AAC.31.8.1234.
152. Koizumi T, Kubo K, Kaneki T, Hanaoka M, Hayano T, Miyahara T, Okada K, Fujimoto K, Yamamoto H, Kobayashi T, Sekiguchi M. 1998. Pharmacokinetic evaluation of amphotericin B in lung tissue: lung lymph distribution after intravenous injection and airspace distribution after aerosolization and inhalation of amphotericin B. Antimicrob. Agents Chemother. 42:1597-1600.
153. Poupelin JC, Philit F, Richard JC, Badet M, Lemasson S, Bayle F, Guerin C. 2006. Pericardial and pleural diffusion of voriconazole during disseminated invasive aspergillosis: report of a case with successful outcome. Intensive Care Med. 32:939-940. http://dx.doi.org/10.1007 /s00134-006-0113-x.
154. Stern JB, Girard P, Caliandro R. 2004. Pleural diffusion of voriconazole in a patient with Aspergillus fumigatus empyema thoracis. Antimicrob. Agents Chemother. 48:1065. http://dx.doi.org/10.1128/AAC.48.3.1065.2004.
155. Weiler S, Bellmann-Weiler R, Joannidis M, Bellmann R. 2007. Penetration of amphotericin B lipid formulations into pleural effusion. Antimicrob. Agents Chemother. 51:4211-4213. http://dx.doi.org/10.1128 /AAC.01087-07.
156. Pennington JE, Block ER, Reynolds HY. 1974. 5-Fluorocytosine and amphotericin B in bronchial secretions. Antimicrob. Agents Chemother. 6:324-326. http://dx.doi.org/10.1128/AAC.6.3.324.
157. Ebden P, Neill P, Farrow PR. 1989. Sputum levels of fluconazole in humans. Antimicrob. Agents Chemother. 33:963-964. http://dx.doi.org /10.1128/AAC.33.6.963.
158. Force RW, Nahata MC. 1995. Salivary concentrations of ketoconazole and fluconazole: implications for drug efficacy in oropharyngeal and esophageal candidiasis. Ann. Pharmacother. 29:10-15.
159. Sermet-Gaudelus I, Lesne-Hulin A, Lenoir G, Singlas E, Berche P, Hennequin C. 2001. Sputum itraconazole concentrations in cystic fibrosis patients. Antimicrob. Agents Chemother. 45:1937-1938. http://dx.doi.org/10.1128/AAC.45.6.1937-1938.2001.
160. Darouiche RO, Setoodeh A, Anaissie EJ. 1995. Potential use of a simplified method for determination of itraconazole levels in plasma and esophageal tissue by using high-performance liquid chromatography. Antimicrob. Agents Chemother. 39:757-759. http://dx.doi.org/10.1128 /AAC.39.3.757.
161. Oude Lashof AM, De Bock R, Herbrecht R, de Pauw BE, Krcmery V, Aoun M, Akova M, Cohen J, Siffnerova H, Egyed M, Ellis M, Marinus A, Sylvester R, Kullberg BJ. 2004. An open multicentre comparative study of the efficacy, safety and tolerance of fluconazole and itraconazole in the treatment of cancer patients with oropharyngeal candidiasis. Eur. J. Cancer 40:1314-1319. http://dx.doi.org/10.1016/j.ejca.2004.03.003.
162. Barbaro G, Di Lorenzo G. 1995. Comparison of therapeutic activity of fluconazole and itraconazole in the treatment of oesophageal candidiasis in AIDS patients: a double-blind, randomized, controlled clinical study. Ital. J. Gastroenterol. 27:175-180.
163. Purkins L, Wood N, Greenhalgh K, Eve MD, Oliver SD, Nichols D. 2003. The pharmacokinetics and safety of intravenous voriconazole-a novel wide-spectrum antifungal agent. Br. J. Clin. Pharmacol. 56:2-9. http://dx.doi.org/10.1046/j.1365-2125.2003.01992.x.
164. Ally R, Schurmann D, Kreisel W, Carosi G, Aguirrebengoa K, Dupont B, Hodges M, Troke P, Romero AJ. 2001. A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin. Infect. Dis. 33:1447-1454. http://dx.doi.org/10.1086/322653.
165. Vazquez JA, Skiest DJ, Nieto L, Northland R, Sanne I, Gogate J, Greaves W, Isaacs R. 2006. A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS. Clin. Infect. Dis. 42:1179-1186. http://dx.doi.org/10.1086/501457.
166. Gubbins PO, Amsden JR, McConnell SA, Anaissie EJ. 2009. Pharmacokinetics and buccal mucosal concentrations of a 15 milligram per kilogram of body weight total dose of liposomal amphotericin B administered as a single dose (15 mg/kg), weekly dose (7.5 mg/kg), or daily dose (1 mg/kg) in peripheral stem cell transplant patients. Antimicrob. Agents Chemother. 53:3664-3674. http://dx.doi.org/10.1128/AAC.01448-08.
167. Petraitis V, Petraitiene R, Groll AH, Sein T, Schaufele RL, Lyman CA, Francesconi A, Bacher J, Piscitelli SC, Walsh TJ. 2001. Dosagedependent antifungal efficacy of V-echinocandin (LY303366) against experimental fluconazole-resistant oropharyngeal and esophageal candidiasis. Antimicrob. Agents Chemother. 45:471-479. http://dx.doi.org/10.1128/AAC.45.2.471-479.2001.
168. Krause DS, Simjee AE, van Rensburg C, Viljoen J, Walsh TJ, Goldstein BP, Wible M, Henkel T. 2004. A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. Clin. Infect. Dis. 39:770-775. http://dx.doi.org/10.1086/423378.
169. Arathoon EG, Gotuzzo E, Noriega LM, Berman RS, DiNubile MJ, Sable CA. 2002. Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases. Antimicrob. Agents Chemother. 46:451-457. http://dx.doi.org/10.1128/AAC.46.2.451-457.2002.
170. de Wet N, Llanos-Cuentas A, Suleiman J, Baraldi E, Krantz EF, Della Negra M, Diekmann-Berndt H. 2004. A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients. Clin. Infect. Dis. 39:842-849. http://dx.doi.org/10.1086/423377.
171. Tang J, Wei H, Liu H, Ji H, Dong D, Zhu D, Wu L. 2010. Pharmacokinetics and biodistribution of itraconazole in rats and mice following intravenous administration in a novel liposome formulation. Drug Deliv. 17:223-230. http://dx.doi.org/10.3109/10717541003667822.
172. Ahmad SR, Singer SJ, Leissa BG. 2001. Congestive heart failure associated with itraconazole. Lancet 357:1766-1767. http://dx.doi.org/10.1016 /S0140-6736(00)04891-1.
173. Qu Y, Fang M, Gao B, Amouzadeh HR, Li N, Narayanan P, Acton P, Lawrence J, Vargas HM. 2013. Itraconazole decreases left ventricular contractility in isolated rabbit heart: mechanism of action. Toxicol. Appl. Pharmacol. 268:113-122. http://dx.doi.org/10.1016/j.taap.2013.01.029.
174. Visser GW, Boele S, Knops GH, Herscheid JD, Hoekstra A. 1985. Synthesis and biodistribution of [18F]-5-fluorocytosine. Nucl. Med. Commun. 6:455-459. http://dx.doi.org/10.1097/00006231-198508000-00005.
175. Ripp SL, Aram JA, Bowman CJ, Chmielewski G, Conte U, Cross DM, Gao H, Lewis EM, Lin J, Liu P, Schlamm HT. 2012. Tissue distribution of anidulafungin in neonatal rats. Birth Defects Res. B Dev. Reprod. Toxicol. 95:89-94. http://dx.doi.org/10.1002/bdrb.20347.
176. Reference deleted.
177. Wasan KM, Grossie VB, Lopez-Berestein G. 1994. Concentrations in serum and distribution in tissue of free and liposomal amphotericin B in rats during continuous intralipid infusion. Antimicrob. Agents Chemother. 38:2224-2226. http://dx.doi.org/10.1128/AAC.38.9.2224.
178. Saliba F, Dupont B. 2008. Renal impairment and amphotericin B formulations in patients with invasive fungal infections. Med. Mycol. 46: 97-112. http://dx.doi.org/10.1080/13693780701730469.
179. Vermes A, Guchelaar HJ, Dankert J. 2000. Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. J. Antimicrob. Chemother. 46:171-179. http://dx.doi.org /10.1093/jac/46.2.171.
180. Reference deleted.
181. Damle BD, Dowell JA, Walsky RL, Weber GL, Stogniew M, Inskeep PB. 2009. In vitro and in vivo studies to characterize the clearance mechanism and potential cytochrome P450 interactions of anidulafungin. Antimicrob. Agents Chemother. 53:1149-1156. http://dx.doi.org/10.1128 /AAC.01279-08.
182. Groll AH, Stergiopoulou T, Roilides E, Walsh TJ. 2005. Micafungin: pharmacology, experimental therapeutics and clinical applications. Expert Opin. Invest. Drugs 14:489-509. http://dx.doi.org/10.1517/13543784.14.4.489.
183. Sobel JD, Bradshaw SK, Lipka CJ, Kartsonis NA. 2007. Caspofungin in the treatment of symptomatic candiduria. Clin. Infect. Dis. 44:e46-e49. http://dx.doi.org/10.1086/510432.
184. Lagrotteria D, Rotstein C, Lee CH. 2007. Treatment of candiduria with micafungin: a case series. Can. J. Infect. Dis. Med. Microbiol. 18:149-150.
185. Walsh TJ, Foulds G, Pizzo PA. 1989. Pharmacokinetics and tissue penetration of fluconazole in rabbits. Antimicrob. Agents Chemother. 33:467-469. http://dx.doi.org/10.1128/AAC.33.4.467.
186. Viviani MA, Cogliati M, Esposto MC, Prigitano A, Tortorano AM. 2006. Four-year persistence of a single Candida albicans genotype causing bloodstream infections in a surgical ward proven by multilocus sequence typing. J. Clin. Microbiol. 44:218-221. http://dx.doi.org/10.1128 /JCM.44.1.218-221.2006.
187. Chen W, Gu B, Wang H, Pan J, Lu W, Hou H. 2008. Development and evaluation of novel itraconazole-loaded intravenous nanoparticles. Int. J. Pharm. 362:133-140. http://dx.doi.org/10.1016/j.ijpharm.2008.05.039.
188. Purkins L, Wood N, Ghahramani P, Greenhalgh K, Allen MJ, Kleinermans D. 2002. Pharmacokinetics and safety of voriconazole following intravenous-to oral-dose escalation regimens. Antimicrob. Agents Chemother. 46:2546-2553. http://dx.doi.org/10.1128/AAC.46.8.2546-2553.2002.
189. Olson JA, Adler-Moore JP, Schwartz J, Jensen GM, Proffitt RT. 2006. Comparative efficacies, toxicities, and tissue concentrations of amphotericin B lipid formulations in a murine pulmonary aspergillosis model. Antimicrob. Agents Chemother. 50:2122-2131. http://dx.doi.org/10.1128/AAC.00315-06.
190. Shrikhande S, Friess H, Issenegger C, Martignoni ME, Yong H, Gloor B, Yeates R, Kleeff J, Büchler MW. 2000. Fluconazole penetration into the pancreas. Antimicrob. Agents Chemother. 44:2569-2571. http://dx.doi.org/10.1128/AAC.44.9.2569-2571.2000.
191. Matuszkiewicz-Rowinska J. 2009. Update on fungal peritonitis and its treatment. Perit. Dial. Int. 29(Suppl 2):S161-S165.
192. Aoyama T, Ogata K, Shimizu M, Hatta S, Masuhara K, Shima Y, Kimura K, Matsumoto Y. 2005. Pharmacokinetics of fluconazole and fosfluconazole after intraperitoneal administration to peritoneal dialysis rats. Drug Metab. Pharmacokinet. 20:485-490. http://dx.doi.org/10.2133/dmpk.20.485.
193. Debruyne D, Ryckelynck JP. 1992. Fluconazole serum, urine, and dialysate levels in CAPD patients. Perit. Dial. Int. 12:328-329.
194. Wong SF, Leung MP, Chan MY. 1997. Pharmacokinetics of fluconazole in children requiring peritoneal dialysis. Clin. Ther. 19:1039-1047. http: //dx.doi.org/10.1016/S0149-2918(97)80056-2.
195. Muther RS, Bennett WM. 1980. Peritoneal clearance of amphotericin B and 5-fluorocytosine. West. J. Med. 133:157-160.
196. van der Voort PH, Boerma EC, Yska JP. 2007. Serum and intraperitoneal levels of amphotericin B and flucytosine during intravenous treatment of critically ill patients with Candida peritonitis. J. Antimicrob. Chemother. 59:952-956. http://dx.doi.org/10.1093/jac/dkm074.
197. Peng LW, Lien YH. 2005. Pharmacokinetics of single, oral-dose voriconazole in peritoneal dialysis patients. Am. J. Kidney Dis. 45:162-166. http://dx.doi.org/10.1053/j.ajkd.2004.09.017.
198. Levin RM, Jason C, Black S, Nickolai D, Potter D, Grossman M. 1982. Management of Candida peritonitis with intravenous amphotericin: peritoneal fluid antibiotic levels. Clin. Pediatr. (Phila.) 21:693-695. http: //dx.doi.org/10.1177/000992288202101110.
199. Weiler S, Bellmann-Weiler R, Dunzendorfer S, Joannidis M, Bellmann R. 2008. Levels of amphotericin B lipid formulations in ascites. J. Antimicrob. Chemother. 62:1163-1164. http://dx.doi.org/10.1093/jac/dkn306.
200. Houang ET, Chappatte O, Byrne D, Macrae PV, Thorpe JE. 1990. Fluconazole levels in plasma and vaginal secretions of patients after a 150-milligram single oral dose and rate of eradication of infection in vaginal candidiasis. Antimicrob. Agents Chemother. 34:909-910. http: //dx.doi.org/10.1128/AAC.34.5.909.
201. Mikamo H, Kawazoe K, Sato Y, Izumi K, Ito T, Ito K, Tamaya T. 1999. Penetration of oral fluconazole into gynecological tissues. Antimicrob. Agents Chemother. 43:148-151.
202. Finley RW, Cleary JD, Goolsby J, Chapman SW. 1995. Fluconazole penetration into the human prostate. Antimicrob. Agents Chemother. 39:553-555. http://dx.doi.org/10.1128/AAC.39.2.553.
203. Luzzati R, Gatti G, Lazzarini L, Limonta D, Vento S, Concia E. 1998. Fluconazole penetration into the prostatic fluid of patients with AIDSassociated cryptococcal meningitis. J. Antimicrob. Chemother. 41:423-424. http://dx.doi.org/10.1093/jac/41.3.423.
204. Conaughty JM, Khurana S, Banovac K, Martinez OV, Eismont FJ. 2004. Antifungal penetration into normal rabbit nucleus pulposus. Spine 29: E289-E293. http://dx.doi.org/10.1097/01.BRS.0000131210.59316.2D.
205. Weers-Pothoff G, Havermans JF, Kamphuis J, Sinnige HA, Meis JF. 1997. Candida tropicalis arthritis in a patient with acute myeloid leukemia successfully treated with fluconazole: case report and review of the literature. Infection 25:109-111. http://dx.doi.org/10.1007/BF02113588.
206. Cushing RD, Fulgenzi WR. 1997. Synovial fluid levels of fluconazole in a patient with Candida parapsilosis prosthetic joint infection who had an excellent clinical response. J. Arthroplasty 12:950. http://dx.doi.org/10.1016/S0883-5403(97)90166-2.
207. Latimer FG, Colitz CM, Campbell NB, Papich MG. 2001. Pharmacokinetics of fluconazole following intravenous and oral administration and body fluid concentrations of fluconazole following repeated oral dosing in horses. Am. J. Vet. Res. 62:1606-1611. http://dx.doi.org/10.2460/ajvr.2001.62.1606.
208. Denes E, Boumediene A, Durox H, Oksman A, Saint-Marcoux F, Darde ML, Gaulier JM. 2007. Voriconazole concentrations in synovial fluid and bone tissues. J. Antimicrob. Chemother. 59:818-819. http://dx.doi.org/10.1093/jac/dkm023.
209. Colitz CM, Latimer FG, Cheng H, Chan KK, Reed SM, Pennick GJ. 2007. Pharmacokinetics of voriconazole following intravenous and oral administration and body fluid concentrations of voriconazole following repeated oral administration in horses. Am. J. Vet. Res. 68:1115-1121. http://dx.doi.org/10.2460/ajvr.68.10.1115.
210. Groll AH, Mickiene D, Piscitelli SC, Walsh TJ. 2000. Distribution of lipid formulations of amphotericin B into bone marrow and fat tissue in rabbits. Antimicrob. Agents Chemother. 44:408-410. http://dx.doi.org /10.1128/AAC.44.2.408-410.2000.
211. Evdoridou J, Roilides E, Bibashi E, Kremenopoulos G. 1997. Multifocal osteoarthritis due to Candida albicans in a neonate: serum level monitoring of liposomal amphotericin B and literature review. Infection 25: 112-116. http://dx.doi.org/10.1007/BF02113589.
212. Weisse ME, Person DA, Berkenbaugh JT, Jr. 1993. Treatment of Candida arthritis with flucytosine and amphotericin B. J. Perinatol. 13:402-404.
213. Fischman AJ, Alpert NM, Livni E, Ray S, Sinclair I, Elmaleh DR, Weiss S, Correia JA, Webb D, Liss R, Strauss W, Rubin RH. 1991. Pharmacokinetics of 18F-labeled fluconazole in rabbits with candidal infections studied with positron emission tomography. J. Pharmacol. Exp. Ther. 259:1351-1359.
214. Wang LH, Fielding RM, Smith PC, Guo LS. 1995. Comparative tissue distribution and elimination of amphotericin B colloidal dispersion (Amphocil) and Fungizone after repeated dosing in rats. Pharm. Res. 12:275-283. http://dx.doi.org/10.1023/A:1016243313027.
215. Sobue S, Sekiguchi K, Nabeshima T. 2004. Intracutaneous distributions of fluconazole, itraconazole, and griseofulvin in guinea pigs and binding to human stratum corneum. Antimicrob. Agents Chemother. 48:216-223. http://dx.doi.org/10.1128/AAC.48.1.216-223.2004.
216. Sasongko L, Williams KM, Day RO, McLachlan AJ. 2003. Human subcutaneous tissue distribution of fluconazole: comparison of microdialysis and suction blister techniques. Br. J. Clin. Pharmacol. 56:551-561. http://dx.doi.org/10.1046/j.1365-2125.2003.01930.x.
217. Faergemann J, Laufen H. 1993. Levels of fluconazole in serum, stratum corneum, epidermis-dermis (without stratum corneum) and eccrine sweat. Clin. Exp. Dermatol. 18:102-106. http://dx.doi.org/10.1111/j.1365-2230.1993.tb00987.x.
218. Wildfeuer A, Faergemann J, Laufen H, Pfaff G, Zimmermann T, Seidl HP, Lach P. 1994. Bioavailability of fluconazole in the skin after oral medication. Mycoses 37:127-130.
219. Savin RC, Drake L, Babel D, Stewart DM, Rich P, Ling MR, Breneman D, Scher RK, Martin AG, Pariser DM, Pariser RJ, Ellis CN, Kang S, Friedman D, Katz HI, McDonald CJ, Muglia J, Webster G, Elewski BE, Leyden JJ, Bucko AD, Tschen EH, Hanifin JM, Morman MR, Shupack JL, Levine N, Lowe NJ, Bergfeld WF, Camisa C, Feingold DS, Konnikov N, Odom RB, Aly R, Greer DL, Hilbert J. 1998. Pharmacokinetics of three once-weekly dosages of fluconazole (150, 300, or 450 mg) in distal subungual onychomycosis of the fingernail. J. Am. Acad. Dermatol. 38:S110-S116. http://dx.doi.org/10.1016/S0190-9622(98)70494-3.
220. Cauwenbergh G, Degreef H, Heykants J, Woestenborghs R, Van Rooy P, Haeverans K. 1988. Pharmacokinetic profile of orally administered itraconazole in human skin. J. Am. Acad. Dermatol. 18:263-268. http: //dx.doi.org/10.1016/S0190-9622(88)70037-7.
221. Schafer-Korting M, Korting HC, Lukacs A, Heykants J, Behrendt H. 1990. Levels of itraconazole in skin blister fluid after a single oral dose and during repetitive administration. J. Am. Acad. Dermatol. 22:211-215. http://dx.doi.org/10.1016/0190-9622(90)70026-E.
222. De Doncker P, Decroix J, Pierard GE, Roelant D, Woestenborghs R, Jacqmin P, Odds F, Heremans A, Dockx P, Roseeuw D. 1996. Antifungal pulse therapy for onychomycosis. A pharmacokinetic and pharmacodynamic investigation of monthly cycles of 1-week pulse therapy with itraconazole. Arch. Dermatol. 132:34-41.
223. Krishna G, Ma L, Martinho M, Prasad P, Wahl J, Tavakkol A. 2011. Determination of posaconazole levels in toenails of adults with onychomycosis following oral treatment with four regimens of posaconazole for 12 or 24 weeks. Antimicrob. Agents Chemother. 55:4424-4426. http: //dx.doi.org/10.1128/AAC.01302-10.
224. Saunte DM, Simmel F, Frimodt-Moller N, Stolle LB, Svejgaard EL, Haedersdal M, Kloft C, Arendrup MC. 2007. In vivo efficacy and pharmacokinetics of voriconazole in an animal model of dermatophytosis. Antimicrob. Agents Chemother. 51:3317-3321. http://dx.doi.org/10.1128 /AAC.01185-06.
225. Fielding RM, Smith PC, Wang LH, Porter J, Guo LS. 1991. Comparative pharmacokinetics of amphotericin B after administration of a novel colloidal delivery system, ABCD, and a conventional formulation to rats. Antimicrob. Agents Chemother. 35:1208-1213. http://dx.doi.org/10.1128/AAC.35.6.1208.
226. Peeters J, Neeskens P, Tollenaere JP, Van Remoortere P, Brewster ME. 2002. Characterization of the interaction of 2-hydroxypropyl--cyclodextrin with itraconazole at pH 2, 4, and 7. J. Pharm. Sci. 91:1414-1422. http://dx.doi.org/10.1002/jps.10126.
227. Prentice AG, Glasmacher A. 2005. Making sense of itraconazole pharmacokinetics. J. Antimicrob. Chemother. 56(Suppl 1):i17-i22. http://dx.doi.org/10.1093/jac/dki220.
228. Keating GM. 2005. Posaconazole. Drugs 65:1553-1567. http://dx.doi.org/10.2165/00003495-200565110-00007.
229. Sandherr M, Maschmeyer G. 2011. Pharmacology and metabolism of voriconazole and posaconazole in the treatment of invasive aspergillosis-review of the literature. Eur. J. Med. Res. 16:139-144. http://dx.doi.org/10.1186/2047-783X-16-4-139.
230. Theuretzbacher U, Ihle F, Derendorf H. 2006. Pharmacokinetic/ pharmacodynamic profile of voriconazole. Clin. Pharmacokinet. 45: 649-663. http://dx.doi.org/10.2165/00003088-200645070-00002.
231. Adedoyin A, Bernardo JF, Swenson CE, Bolsack LE, Horwith G, DeWit S, Kelly E, Klasterksy J, Sculier JP, DeValeriola D, Anaissie E, Lopez-Berestein G, Llanos-Cuentas A, Boyle A, Branch RA. 1997. Pharmacokinetic profile of ABELCET (amphotericin B lipid complex injection): combined experience from phase I and phase II studies. Antimicrob. Agents Chemother. 41:2201-2208.
232. Linden PK. 2003. Amphotericin B lipid complex for the treatment of invasive fungal infections. Expert Opin. Pharmacother. 4:2099-2110. http://dx.doi.org/10.1517/14656566.4.11.2099.
233. Bekersky I, Fielding RM, Dressler DE, Lee JW, Buell DN, Walsh TJ. 2002. Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans. Antimicrob. Agents Chemother. 46:828-833. http://dx.doi.org/10.1128 /AAC.46.3.828-833.2002.
234. Sanders SW, Buchi KN, Goddard MS, Lang JK, Tolman KG. 1991. Single-dose pharmacokinetics and tolerance of a cholesteryl sulfate complex of amphotericin B administered to healthy volunteers. Antimicrob. Agents Chemother. 35:1029-1034. http://dx.doi.org/10.1128/AAC.35.6.1029.
235. Kim R, Khachikian D, Reboli AC. 2007. A comparative evaluation of properties and clinical efficacy of the echinocandins. Expert Opin. Pharmacother. 8:1479-1492. http://dx.doi.org/10.1517/14656566.8.10.1479.
236. Theuretzbacher U. 2004. Pharmacokinetics/pharmacodynamics of echinocandins. Eur. J. Clin. Microbiol. Infect. Dis. 23:805-812. http://dx.doi.org/10.1007/s10096-004-1228-z.
237. Dellenbach P. 1989. Penetration of fluconazole into vaginal tissues and secretions, p 19-22. In Richardson RG (ed), Fluconazole and its role in vaginal candidiasis. Royal Society of Medicine congress and symposium series, vol 160. RSM Services Ltd, London, United Kingdom.
238. Rieder-Nelissen CM, Hasse J, Yeates RA, Sarnow E. 1997. Fluconazole concentrations in pulmonary tissue and pericardial fluid. Infection 25: 192-194. http://dx.doi.org/10.1007/BF02113615.
239. Seishima M, Oyama Z, Oda M, Ishigo S. 2004. Distribution of an antifungal drug, itraconazole, in pathological and non-pathological tissues. Eur. J. Dermatol. 14:24-27.
240. Larosa E, Cauwenbergh G, Cilli P, Woestenborghs R, Heykants J. 1986. Itraconazole pharmacokinetics in the female genital tract: plasma and tissue levels in patients undergoing hysterectomy after a single dose of 200 mg itraconazole. Eur. J. Obstet. Gynecol. Reprod. Biol. 23:85-89. http://dx.doi.org/10.1016/0028-2243(86)90109-7.
241. Viviani MA, Tortorano AM, Woenstenbroghs R, Cauwenbergh G. 1987. Experience with itraconazole in deep mycoses in northern Italy. Mykosen 30:233-244.
242. Davis JL, Salmon JH, Papich MG. 2005. Pharmacokinetics and tissue distribution of itraconazole after oral and intravenous administration to horses. Am. J. Vet. Res. 66:1694-1701. http://dx.doi.org/10.2460/ajvr.2005.66.1694.
243. Schwartz S, Runhke M. 2008. Aspergillus sinusitis and cerebral aspergillosis, p 301-322. In Latge JP, Steinbach WJ (ed), Aspergillus fumigatus and aspergillosis, 1st ed, vol 1. ASM Press, Washington, DC.
244. Sponsel WE, Graybill JR, Nevarez HL, Dang D. 2002. Ocular and systemic posaconazole (SCH-56592) treatment of invasive Fusarium solani keratitis and endophthalmitis. Br. J. Ophthalmol. 86:829-830. http: //dx.doi.org/10.1136/bjo.86.7.829-a.
245. Reference deleted.
246. Ramaswamy M, Peteherych KD, Kennedy AL, Wasan KM. 2001. Amphotericin B lipid complex or amphotericin B multiple-dose administration to rabbits with elevated plasma cholesterol levels: pharmacokinetics in plasma and blood, plasma lipoprotein levels, distribution in tissues, and renal toxicities. Antimicrob. Agents Chemother. 45:1184-1191. http://dx.doi.org/10.1128/AAC.45.4.1184-1191.2001.
247. Kutty K, Neicheril JC. 1987. Treatment of pleural blastomycosis: penetration of amphotericin B into the pleural fluid. J. Infect. Dis. 156:689-690. http://dx.doi.org/10.1093/infdis/156.4.689.
248. Demartini G, Lequaglie C, Brega Massone P, Scaglione F, Fraschini F. 2005. Penetration of amphotericin B in human lung tissue after single liposomal amphotericin B (AmBisome) infusion. J. Chemother. 17:82-85. http://dx.doi.org/10.1287/ijoc.1030.0050.
249. Goldblum D, Rohrer K, Frueh BE, Theurillat R, Thormann W, Zimmerli S. 2004. Corneal concentrations following systemic administration of amphotericin B and its lipid preparations in a rabbit model. Ophthalmol. Res. 36:172-176. http://dx.doi.org/10.1159/000077331.
250. Shadomy S. 1970. Further in vitro studies with 5-fluorocytosine. Infect. Immun. 2:484-488.
251. Moriyama B, Ditullio M, Wilson E, Henning SA, Penzak SR, Danner RL, Pennick G, Rinaldi MG, Zelazny AM, Gea-Banacloche J, Barrett AJ, Walsh TJ. 2011. Pharmacokinetics of anidulafungin in pleural fluid during the treatment of a patient with Candida empyema. Antimicrob. Agents Chemother. 55:2478-2480. http://dx.doi.org/10.1128/AAC.01560-10.
252. Okugawa S, Ota Y, Tatsuno K, Tsukada K, Kishino S, Koike K. 2007. A case of invasive central nervous system aspergillosis treated with micafungin with monitoring of micafungin concentrations in the cerebrospinal fluid. Scand. J. Infect. Dis. 39:344-346. http://dx.doi.org/10.1080 /00365540600951333.
253. Logan S, Rajan M, Graham E, Johnson E, Klein J. 2010. A case of aspergillus endophthalmitis in an immunocompetent woman: intraocular penetration of oral voriconazole: a case report. Cases J. 3:31-32. http://dx.doi.org/10.1186/1757-1626-3-31.
254. Epaulard O, Leccia MT, Blanche S, Chosidow O, Mamzer-Bruneel MF, Ravaud P, Thiebaut A, Villier C, Lortholary O. 2011. Phototoxicity and photocarcinogenesis associated with voriconazole. Med. Mal. Infect. 41: 639-645. http://dx.doi.org/10.1016/j.medmal.2011.09.016.
255. Zwald FO, Spratt M, Lemos BD, Veledar E, Lawrence C, Marshall Lyon G, Chen SC. 2012. Duration of voriconazole exposure: an independent risk factor for skin cancer after lung transplantation. Dermatol. Surg. 38:1369-1374. http://dx.doi.org/10.1111/j.1524-4725.2012.02418.x.
256. McLaughlin JM, Equils O, Somerville KT, Aram JA, Schlamm HT, Welch VL, Mardekian J, Barbers RG. 12 March 2013. Risk-adjusted relationship between voriconazole utilization and non-melanoma skin cancer among lung and heart/lung transplant patients. Transpl. Infect. Dis. http://dx.doi.org/10.1111/tid.12063.
257. Kravitz JN, Berry MW, Schabel SI, Judson MA. 2013. A modern series of percutaneous intracavitary instillation of amphotericin B for the treatment of severe hemoptysis from pulmonary aspergilloma. Chest 143: 1414-1421. http://dx.doi.org/10.1378/chest.12-1784.
258. Tan K, Brayshaw N, Tomaszewski K, Troke P, Wood N. 2006. Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities. J. Clin. Pharmacol. 46:235-243. http://dx.doi.org/10.1177/0091270005283837.
259. Rodvold KA, Nicolau DP, Lodise TP, Khashab M, Noel GJ, Kahn JB, Gotfried M, Murray SA, Nicholson S, Laohavaleeson S, Tessier PR, Drusano GL. 2009. Identifying exposure targets for treatment of staphylococcal pneumonia with ceftobiprole. Antimicrob. Agents Chemother. 53:3294-3301. http://dx.doi.org/10.1128/AAC.00144-09.
260. Aboagye EO, Artemov D, Senter PD, Bhujwalla ZM. 1998. Intratumoral conversion of 5-fluorocytosine to 5-fluorouracil by monoclonal antibody-cytosine deaminase conjugates: noninvasive detection of prodrug activation by magnetic resonance spectroscopy and spectroscopic imaging. Cancer Res. 58:4075-4078.
261. Khatib-Shahidi S, Andersson M, Herman JL, Gillespie TA, Caprioli RM. 2006. Direct molecular analysis of whole-body animal tissue sections by imaging MALDI mass spectrometry. Anal. Chem. 78:6448-6456. http://dx.doi.org/10.1021/ac060788p.
262. Hope WW, Petraitis V, Petraitiene R, Aghamolla T, Bacher J, Walsh TJ. 2010. The initial 96 hours of invasive pulmonary aspergillosis: histopathology, comparative kinetics of galactomannan and (1¡3)--D-glucan, and consequences of delayed antifungal therapy. Antimicrob. Agents Chemother. 54:4879-4886. http://dx.doi.org/10.1128/AAC.00673-10.
263. O'Connor L, Livermore J, Sharp AD, Goodwin J, Gregson L, Howard SJ, Felton TW, Schwartz JA, Neely MN, Harrison TS, Perfect JR, Hope WW. 2013. Pharmacodynamics of liposomal amphotericin B and flucytosine for cryptococcal meningoencephalitis: safe and effective regimens for immunocompromised patients. J. Infect. Dis. 208:351-361. http://dx.doi.org/10.1093/infdis/jit164.